HERON THERAPEUTICS, INC. /DE/ (HRTX) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 395 transactions totaling $188.5M, demonstrating a bearish sentiment with -$63.5M in net insider flow. The most recent transaction on Jan 31, 2026 involved a transaction of 34,789 shares valued at $0.
No significant insider buying has been recorded for HRTX in the recent period.
No significant insider selling has been recorded for HRTX in the recent period.
Based on recent SEC filings, insider sentiment for HRTX is bearish with an Insider Alignment Score of 33/100 and a net flow of -$63.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at HERON THERAPEUTICS, INC. /DE/ (HRTX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading HRTX stock, having executed 395 transactions in the past 90 days. The most active insider is Capital Management Llc Tang (Executive), who has made 4 transactions totaling $111.3M.
Get notified when executives and directors at HRTX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | A. Collard Craig | Executive | Option Exercise | 34,789 | $N/A | $0 | |
| Jan 31, 2026 | A. Collard Craig | Executive | Option Exercise | 34,789 | $N/A | $0 | |
| Jan 31, 2026 | P. Forbes William | EVP, Chief Development Officer | Option Exercise | 11,695 | $N/A | $0 | |
| Jan 31, 2026 | P. Forbes William | EVP, Chief Development Officer | Option Exercise | 11,695 | $N/A | $0 | |
| Jan 31, 2026 | Duarte Ira | EVP, Chief Financial Officer | Option Exercise | 11,695 | $N/A | $0 | C-Suite |
| Jan 31, 2026 | Duarte Ira | EVP, Chief Financial Officer | Option Exercise | 11,695 | $N/A | $0 | C-Suite |
| Jan 30, 2026 | Dissanaike Sharmila | Executive | Award | 53,960 | $N/A | $0 | |
| Jan 30, 2026 | Cusack Thomas | Executive | Award | 53,960 | $N/A | $0 | |
| Jan 30, 2026 | A. Johnson Craig | Executive | Award | 53,960 | $N/A | $0 | |
| Jan 30, 2026 | Kaseta Michael | Executive | Award | 53,960 | $N/A | $0 | |
| Jan 30, 2026 | Christian Waage | Executive | Award | 53,960 | $N/A | $0 | |
| Jan 30, 2026 | Morgan Adam | Executive | Award | 53,960 | $N/A | $0 | |
| Jan 19, 2026 | P. Forbes William | EVP, Chief Development Officer | Option Exercise | 3,875 | $N/A | $0 | |
| Jan 19, 2026 | P. Forbes William | EVP, Chief Development Officer | Option Exercise | 3,875 | $N/A | $0 | |
| Jan 19, 2026 | A. Collard Craig | Executive | Option Exercise | 13,797 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 84 | $126.0M | 60.4% |
Purchase(P) | 21 | $62.5M | 30.0% |
Exercise(M) | 147 | $13.9M | 6.7% |
Payment(F) | 59 | $5.9M | 2.8% |
Other(J) | 31 | $372.1K | 0.2% |
Award(A) | 26 | $0 | 0.0% |
Conversion(C) | 1 | $0 | 0.0% |
Gift(G) | 26 | $0 | 0.0% |
Insider selling pressure at HERON THERAPEUTICS, INC. /DE/ has increased, with 26 insiders executing 395 transactions across all time. Total sales of $126.0M significantly outpace purchases of $62.5M, resulting in a net outflow of $63.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.